Prolactin is a hormone made by the pituitary gland. Its main role is supporting milk production after pregnancy, but it influences sexual function, fertility, and bone health throughout adult life. Dopamine normally suppresses prolactin release. Antipsychotics block dopamine. As a result, almost every antipsychotic raises prolactin to some degree — and a subset raises it dramatically.
Hyperprolactinemia is a common, often under-recognised side effect of dopamine-blocking antipsychotics, with symptoms ranging from missed periods and breast tenderness to sexual dysfunction and long-term bone loss, and it varies enormously by which antipsychotic is used.
Which antipsychotics raise prolactin most
- Highest: risperidone, paliperidone
- High: haloperidol, fluphenazine, perphenazine, amisulpride (where available)
- Moderate: olanzapine, ziprasidone
- Low: asenapine, lurasidone
- Minimal or none: aripiprazole, brexpiprazole, cariprazine, quetiapine, clozapine, lumateperone
Aripiprazole's partial-agonist mechanism actually lowers prolactin in many patients, which is why it is sometimes added at low dose to reduce hyperprolactinemia caused by other antipsychotics.
What hyperprolactinemia feels like
Symptoms vary enormously. Some people with significantly elevated prolactin have no symptoms at all. Others have:
- Women: menstrual irregularity, missed periods, infertility, decreased vaginal lubrication, decreased libido, breast tenderness, galactorrhea (milk production)
- Men: decreased libido, erectile dysfunction, infertility, breast enlargement (gynecomastia), galactorrhea, reduced facial hair
- Both: bone density loss over time, possible mood symptoms
Why bone matters
Long-term hyperprolactinemia suppresses estrogen in women and testosterone in men, both of which support bone density. Several long-term studies of patients on prolactin-raising antipsychotics have found increased rates of osteopenia and osteoporosis, and possibly fractures. The clinical significance is most established for patients on long-term high-dose risperidone or paliperidone. Bone density screening is increasingly recommended for these patients, especially if symptoms of estrogen or testosterone deficiency are present.
Monitoring
The American Psychiatric Association schizophrenia guideline and the NICE schizophrenia guideline both recommend asking about symptoms of hyperprolactinemia at every visit on prolactin-raising agents. A baseline prolactin level is reasonable when starting any of the high-risk medications, with follow-up testing if symptoms develop. Routine prolactin monitoring in asymptomatic patients on low-prolactin agents is generally not recommended.
Normal prolactin is roughly:
- Women: <25 ng/mL
- Men: <20 ng/mL
Antipsychotic-induced hyperprolactinemia typically produces levels in the 25–100 ng/mL range. Levels above 200 ng/mL on antipsychotic monotherapy are unusual and prompt evaluation for a pituitary adenoma (prolactinoma), often with brain MRI. Pregnancy should always be ruled out as a cause in women of childbearing potential.
Treatment options
1. Watch and wait
If prolactin is mildly elevated and the patient has no symptoms, monitoring without intervention is reasonable.
2. Lower the dose
Prolactin elevation is dose-related for most agents. A dose reduction often resolves both the lab abnormality and the symptoms.
3. Switch to a prolactin-sparing antipsychotic
Switching from risperidone or paliperidone to aripiprazole, lumateperone, quetiapine, or clozapine usually normalises prolactin within weeks. The trade-off is the risk of psychiatric instability during the switch.
4. Add low-dose aripiprazole
Adding aripiprazole 5–10 mg daily to a prolactin-raising antipsychotic has consistent evidence for reducing prolactin without losing antipsychotic efficacy. This strategy is increasingly used in clinical practice.
5. Hormonal replacement (case-dependent)
For long-term cases with documented bone or sexual symptoms that cannot be addressed by changing the antipsychotic, estrogen or testosterone replacement is sometimes used in consultation with endocrinology.
6. Dopamine agonists (rarely in psychiatric patients)
Cabergoline and bromocriptine are the standard treatment for non-antipsychotic hyperprolactinemia. They are used cautiously in patients with psychotic disorders because increasing dopamine can worsen psychosis. When used, low doses with close monitoring are typical.
Why this is so often missed
The symptoms — missed periods, low libido, erectile dysfunction — are sensitive topics that patients are reluctant to bring up and clinicians frequently skip over. Many patients on long-term risperidone go years without anyone asking about menstrual cycles or sexual function. Asking is the single biggest change a clinician (or a patient) can make.
New milk production from the breasts (especially in someone not pregnant or breastfeeding), persistent missed periods, vision changes, or severe headaches on an antipsychotic warrant prompt evaluation, including a prolactin level.
The bottom line
Hyperprolactinemia is one of the most under-recognised antipsychotic side effects, and one of the most addressable. The conversation begins with the prescriber asking about symptoms — and the patient knowing that the symptoms are connected to the medication. With the rise of low-prolactin alternatives and the option of low-dose aripiprazole augmentation, persistent symptomatic hyperprolactinemia is increasingly a problem with solutions.
For more, see our hyperprolactinemia overview, prolactin monitoring, and sexual side effects deep dive.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.